Leerink Partnrs Has Pessimistic Outlook of REGN Q2 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of Regeneron Pharmaceuticals in a report released on Wednesday, June 11th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $7.71 per share for the quarter, down from their previous forecast of $8.22. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q3 2025 earnings at $8.77 EPS, Q4 2025 earnings at $8.71 EPS, FY2025 earnings at $31.40 EPS and FY2026 earnings at $32.49 EPS.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research report on Monday, June 9th. Royal Bank of Canada cut shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 target price for the company. in a research report on Friday, May 30th. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, June 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Finally, Guggenheim restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $529.24 on Monday. The company has a 50-day simple moving average of $563.19 and a two-hundred day simple moving average of $648.52. The stock has a market capitalization of $57.14 billion, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% compared to the same quarter last year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of REGN. Capital International Investors increased its position in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $802,036,000. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Nuveen LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth $343,764,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.